1. Home
  2. HRMY vs RDY Comparison

HRMY vs RDY Comparison

Compare HRMY & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HRMY
  • RDY
  • Stock Information
  • Founded
  • HRMY 2017
  • RDY 1984
  • Country
  • HRMY United States
  • RDY India
  • Employees
  • HRMY N/A
  • RDY N/A
  • Industry
  • HRMY Biotechnology: Pharmaceutical Preparations
  • RDY Biotechnology: Pharmaceutical Preparations
  • Sector
  • HRMY Health Care
  • RDY Health Care
  • Exchange
  • HRMY Nasdaq
  • RDY Nasdaq
  • Market Cap
  • HRMY 1.8B
  • RDY 2.1B
  • IPO Year
  • HRMY 2020
  • RDY N/A
  • Fundamental
  • Price
  • HRMY $34.00
  • RDY $14.53
  • Analyst Decision
  • HRMY Strong Buy
  • RDY Strong Buy
  • Analyst Count
  • HRMY 9
  • RDY 2
  • Target Price
  • HRMY $54.44
  • RDY $16.95
  • AVG Volume (30 Days)
  • HRMY 642.5K
  • RDY 1.5M
  • Earning Date
  • HRMY 08-05-2025
  • RDY 07-28-2025
  • Dividend Yield
  • HRMY N/A
  • RDY 0.56%
  • EPS Growth
  • HRMY 13.13
  • RDY 1.47
  • EPS
  • HRMY 2.62
  • RDY 0.79
  • Revenue
  • HRMY $744,852,000.00
  • RDY $3,809,801,863.00
  • Revenue This Year
  • HRMY $20.10
  • RDY $10.24
  • Revenue Next Year
  • HRMY $18.01
  • RDY N/A
  • P/E Ratio
  • HRMY $13.10
  • RDY $18.39
  • Revenue Growth
  • HRMY 20.62
  • RDY 16.61
  • 52 Week Low
  • HRMY $26.47
  • RDY $12.26
  • 52 Week High
  • HRMY $41.61
  • RDY $16.89
  • Technical
  • Relative Strength Index (RSI)
  • HRMY 58.91
  • RDY 37.98
  • Support Level
  • HRMY $31.70
  • RDY $14.81
  • Resistance Level
  • HRMY $35.08
  • RDY $15.25
  • Average True Range (ATR)
  • HRMY 0.95
  • RDY 0.20
  • MACD
  • HRMY 0.27
  • RDY -0.12
  • Stochastic Oscillator
  • HRMY 71.80
  • RDY 5.18

About HRMY Harmony Biosciences Holdings Inc.

Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

About RDY Dr. Reddy's Laboratories Ltd

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Share on Social Networks: